Intra-Cellular Therapies Inc
(MEX:ITCI)
MXN
1529.77
0 (0%)
Market Cap: 183.55 Bil
Enterprise Value: 163.69 Bil
PE Ratio: 0
PB Ratio: 8.01
GF Score: 38/100 Intra-Cellular Therapies Inc at UBS BioPharma Conference Transcript
Nov 08, 2023 / 04:00PM GMT
Release Date Price:
MXN1135.67
Ashwani Verma
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst
Thanks, everybody. Welcome to UBS Biopharma Conference in Miami. My name is Ash Verma. I'm a SMID-cap biotech and spec pharma analyst at UBS, and our next company is Intra-Cellular Therapies. And with me today, I have Sharon Mates and Mark Neumann from Intra-Cellular. How are you doing?
Mark Neumann
Intra-Cellular Therapies, Inc. - EVP & Chief Commercial Officer
Very good.
Ashwani Verma;Sharon Mates
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst;Intra-Cellular
Yes. Thanks for joining us. I mean so yes, like Intra-Cellular Therapies or ITCI, it's something that I've been following for a while seen us focus biotherapy. Sharon, it might be helpful if you can just give like a quick background for investors that might not be familiar with the story, and then we can dive into the questions.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot